These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 26733502)
1. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours. Vitali E; Cambiaghi V; Zerbi A; Carnaghi C; Colombo P; Peverelli E; Spada A; Mantovani G; Lania AG Endocr Relat Cancer; 2016 Mar; 23(3):181-90. PubMed ID: 26733502 [TBL] [Abstract][Full Text] [Related]
2. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment. Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331 [TBL] [Abstract][Full Text] [Related]
3. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells. Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401 [TBL] [Abstract][Full Text] [Related]
4. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Peverelli E; Giardino E; Treppiedi D; Vitali E; Cambiaghi V; Locatelli M; Lasio GB; Spada A; Lania AG; Mantovani G Endocrinology; 2014 Aug; 155(8):2932-41. PubMed ID: 24828612 [TBL] [Abstract][Full Text] [Related]
5. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Vitali E; Piccini S; Trivellin G; Smiroldo V; Lavezzi E; Zerbi A; Pepe G; Lania AG Mol Cell Endocrinol; 2021 May; 527():111226. PubMed ID: 33675866 [TBL] [Abstract][Full Text] [Related]
6. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells. Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507 [TBL] [Abstract][Full Text] [Related]
7. Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Cambiaghi V; Vitali E; Morone D; Peverelli E; Spada A; Mantovani G; Lania AG Endocrine; 2017 Apr; 56(1):146-157. PubMed ID: 27406390 [TBL] [Abstract][Full Text] [Related]
8. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563 [TBL] [Abstract][Full Text] [Related]
10. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099 [TBL] [Abstract][Full Text] [Related]
12. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation. Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Carrere N; Vernejoul F; Souque A; Asnacios A; Vaysse N; Pradayrol L; Susini C; Buscail L; Cordelier P Hum Gene Ther; 2005 Oct; 16(10):1175-93. PubMed ID: 16218779 [TBL] [Abstract][Full Text] [Related]
14. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010 [TBL] [Abstract][Full Text] [Related]
15. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939 [TBL] [Abstract][Full Text] [Related]
16. Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation. Peverelli E; Giardino E; Vitali E; Treppiedi D; Lania AG; Mantovani G Horm Metab Res; 2014 Nov; 46(12):845-53. PubMed ID: 25068602 [TBL] [Abstract][Full Text] [Related]
17. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors? Körner M; Waser B; Reubi JC Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947 [TBL] [Abstract][Full Text] [Related]